Estêvão-Costa M I, Diniz C R, Magalhães A, Markland F S, Sanchez E F
Centro de Pesquisa e Desenvolvimento, Fundaçao Ezequiel Dias, 30510-010, Belo Horizonte, Brazil.
Thromb Res. 2000 Aug 15;99(4):363-76. doi: 10.1016/s0049-3848(00)00259-0.
The zinc endopeptidases mutalysin I (100 kDa) and mutalysin II (22.5 kDa) have been previously isolated from bushmaster (Lachesis muta muta) snake venom. Hemorrhagic activity was observed with as little as 0.5 microg (2000 units/mg) and 17.8 microg (56.2 units/mg) for mutalysin I and II, respectively. Additionally, the proteases hydrolyse the Aalpha>Bbeta chain of fibrinogen without clot formation. The specific fibrinogenolytic activity was estimated as 5. 25 and 16.3 micromol fibrinogen/min/micromol protein for mutalysin I and II, respectively. In vitro, the enzymes act directly on fibrin and are not inhibited by serine proteinase inhibitors (SERPINS). Analysis by SDS-PAGE of fibrin hydrolysis by both enzymes showed that mutalysin II (0.22 microM) completely digested the alpha- and gamma-gamma chains and partially the beta-chain (in 120 min incubation). In contrast, mutalysin I (three fold higher concentration than mutalysin II) hydrolyzed selectively the alpha-chain of fibrin leaving the beta and gamma-gamma chains unaffected. Unlike with the plasminogen activator-based thrombolytic agents (e.g., streptokinase), mutalysins do not activate plasminogen. Neither enzyme had an effect on protein C activation. Mutalysin II does not inhibit platelet aggregation in human PRP induced by collagen or ADP. However, mutalysin I showed a selective inhibitory effect on collagen-induced aggregation of human PRP; it did not affect platelet aggregation with ADP as the agonist. The present investigation demonstrates that both native and EDTA-inactivated mutalysin I dose dependently blocked aggregation of human PRP elicited by 10 microg/mL of collagen with an IC(50) of 180 and 580 nM, respectively. These studies suggest that, in addition to the metalloprotease region of mutalysin I, the disintegrin-like domain also participates in the inhibitory effect. The proteolytic activity of mutalysin II against dimethylcasein and fibrin was completely abolished by alpha2-macroglobulin (alpha2-M). The stoichiometry of inhibition was 1.0 mol of enzyme per mol of alpha2-M. In contrast, the proteolytic effect of mutalysin I against the same substrates was not significantly inhibited by alpha2-M. Therefore, the data explain why mutalysin I contributes significantly not only to local but also to systemic bleeding associated with the observed pathological effects of the venom.
锌内肽酶互变异构酶I(100 kDa)和互变异构酶II(22.5 kDa)先前已从巨蝮(Lachesis muta muta)蛇毒中分离出来。互变异构酶I和II分别在低至0.5微克(2000单位/毫克)和17.8微克(56.2单位/毫克)时即可观察到出血活性。此外,这些蛋白酶可水解纤维蛋白原的Aα>Bβ链而不形成凝块。互变异构酶I和II的特异性纤维蛋白原水解活性分别估计为5.25和16.3微摩尔纤维蛋白原/分钟/微摩尔蛋白。在体外,这些酶直接作用于纤维蛋白,不受丝氨酸蛋白酶抑制剂(丝氨酸蛋白酶抑制剂)的抑制。通过SDS-PAGE分析两种酶对纤维蛋白的水解作用表明,互变异构酶II(0.22微摩尔)在120分钟孵育后完全消化了α链和γ-γ链,并部分消化了β链。相比之下,互变异构酶I(浓度比互变异构酶II高3倍)选择性水解纤维蛋白的α链,而β链和γ-γ链不受影响。与基于纤溶酶原激活剂的溶栓剂(如链激酶)不同,互变异构酶不激活纤溶酶原。两种酶对蛋白C的激活均无影响。互变异构酶II不抑制胶原蛋白或ADP诱导的人富血小板血浆(PRP)中的血小板聚集。然而,互变异构酶I对胶原蛋白诱导的人PRP聚集表现出选择性抑制作用;它不影响以ADP为激动剂的血小板聚集。本研究表明,天然的和经EDTA灭活的互变异构酶I均剂量依赖性地阻断了10微克/毫升胶原蛋白引发的人PRP聚集,其IC50分别为180和580纳摩尔。这些研究表明,除了互变异构酶I的金属蛋白酶区域外,类去整合素结构域也参与了抑制作用。互变异构酶II对二甲基酪蛋白和纤维蛋白的蛋白水解活性被α2-巨球蛋白(α2-M)完全消除。抑制的化学计量比为每摩尔α2-M 1.0摩尔酶。相比之下,互变异构酶I对相同底物的蛋白水解作用未被α2-M显著抑制。因此,这些数据解释了为什么互变异构酶I不仅对与毒液观察到的病理效应相关的局部出血,而且对全身出血都有显著贡献。